Accueil・Liste d'Actions・Cerus Corp

Cerus Corp

Fermé

SecteurSoins de santé

2.34 1.3

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.2

Max

2.35

Chiffres clés
By Trading Economics
Revenu	-1.3M -3M
Ventes	-2.5M 57M
BPA	-0.01
Marge bénéficiaire	-5.191
Employés	261
EBITDA	-1.5M -712K

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+120.26% upside

Dividendes
By Acuity
Prochains Résultats	5 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-182M 433M
Ouverture précédente	1.04
Clôture précédente	2.34

Sentiment de l'Actualité

By Acuity

50%

156 / 340 Classement par Healthcare

Cerus Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

5 août 2026, 19:43 UTC

Cerus Corp shares are higher Wednesday, recovering from an earlier decline amid high trading volume. Broader market sentiment is influenced by ADP's employment report.

4 août 2026, 19:11 UTC

Correlated Moves

Cerus Corp shares are higher amid increased trading volume and positive market trends, despite concerns over declining U.S. core factory orders.

3 août 2026, 19:56 UTC

Correlated Moves

Cerus Corp shares are higher, supported by broader market strength and a rally in the health care supplies sector. The stock remains below its 20-day moving average.

31 juil. 2026, 23:06 UTC

Cerus Corp shares are higher in after-market trading, reflecting a notable increase since Friday's close, despite being below its 20-day moving average.

30 juil. 2026, 23:41 UTC

News

Cerus Corporation shares declined in after-market hours following a revenue miss and lowered full-year guidance, despite second-quarter earnings matching estimates.

29 juil. 2026, 19:56 UTC

Macro Event

Cerus Corp shares are lower as macroeconomic factors, including steady interest rates and rising oil prices, create market volatility. The stock is near its one-month low.

28 juil. 2026, 16:02 UTC

Cerus Corp shares are lower today, reflecting broader market pressures amid a risk-off sentiment following declines in tech-heavy indices like Japan's Nikkei 225.

27 juil. 2026, 20:07 UTC

Cerus Corp shares are higher in Monday's session, reaching a peak of 6.12%. Broader market factors include declining oil prices and lower Treasury yields.

24 juil. 2026, 19:06 UTC

Cerus Corp shares are higher, supported by a decline in crude oil prices that eased inflationary pressures. The stock remains below its 20-day moving average.

23 juil. 2026, 09:01 UTC

Cerus Corp shares are lower in pre-market hours, continuing a downward trend. The stock remains significantly below its 20-day moving average.

22 juil. 2026, 15:46 UTC

Cerus Corp. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average after a month of gains.

21 juil. 2026, 21:41 UTC

Cerus Corp shares are lower in after-market hours, declining steadily after an early peak. No specific news was identified to explain the movement.

Comparaison

Variation de prix

Cerus Corp prévision

Objectif de Prix

By TipRanks

120.26% hausse

Prévisions sur 12 Mois

Moyen 5 USD 120.26%

Haut 5 USD

Bas 5 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

156 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.